Análisis de la acción Madrigal Pharmaceuticals Inc (MDGL)MDGLMadrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Madrigal Pharmaceuticals is a good buy right now due to its current price of $449.74, which is significantly lower than analyst price targets, with Goldman Sachs at $704 and Citi at $725. The company has shown strong sales growth with Rezdiffra achieving $364.3 million in Q2, a 71% year-over-year increase, indicating robust market demand. However, the main risk is the high forward P/E ratio of 78.125, suggesting that the stock is priced for significant future growth, which may not materialize if market conditions change.

3 analysts cover MDGL: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 636.22.